HeartSciences Inc. Cash Flow Conversion Efficiency
HeartSciences Inc. cash flow conversion efficiency. Based on the latest financial reports, HeartSciences Inc. (HSCS) has a cash flow conversion efficiency ratio of 648.679x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.32 Billion) by net assets ($-2.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of HeartSciences Inc. (2020–2026)
Cash flow conversion efficiency of HeartSciences Inc. from 2020 to 2026. This chart illustrates how HeartSciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View HSCS share price today for real-time trading data and today's change.
HeartSciences Inc. Cash Flow Conversion Ratio Explained
HeartSciences Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
HeartSciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HeartSciences Inc. ranked by their cash flow conversion efficiency. Also see market cap of HeartSciences Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Investsmart Group Ltd
AU:INV
|
0.282x |
|
P3 Health Partners Inc
NASDAQ:PIII
|
-0.003x |
|
Xintela AB
ST:XINT
|
0.242x |
|
Megapolitan Developments Tbk
JK:EMDE
|
-0.004x |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
-0.055x |
|
Aksara Global Development Tbk PT
JK:GAMA
|
-0.007x |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
-0.061x |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
N/A |
Annual Cash Flow Conversion Efficiency for HeartSciences Inc. (2020–2026)
The table below shows the annual cash flow conversion efficiency of HeartSciences Inc. from 2020 to 2026. Review HSCS financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | $226.06 Million | $-7.43 Million | -0.033x | +99.91% |
| 2025-04-30 | $205.17K | $-7.41 Million | -36.131x | -4255.39% |
| 2024-04-30 | $7.32 Million | $-6.07 Million | -0.830x | +96.69% |
| 2023-04-30 | $230.56K | $-5.77 Million | -25.042x | -4261.43% |
| 2022-04-30 | $-6.06 Million | $-3.64 Million | 0.602x | -53.14% |
| 2021-04-30 | $-1.91 Million | $-2.45 Million | 1.284x | +110.55% |
| 2020-04-30 | $315.55K | $-3.84 Million | -12.169x | -- |
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related… Read more